MALLINCKRODT INC /MO
8-K, 1997-10-16
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: EASTGROUP PROPERTIES INC, 8-K, 1997-10-16
Next: COMPUTER DYNAMICS INC, SC 13D, 1997-10-16



                       SECURITIES AND EXCHANGE COMMISSION



                             Washington, D.C.  20549



                                      FORM 8-K


                                   CURRENT REPORT



                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934



                                  October 15, 1997




                                   Mallinckrodt Inc.
               (Exact name of registrant as specified in its charter)




             New York               1-483            36-1263901
  (State or other jurisdiction   (Commission     (I.R.S. Employer
   of incorporation)              File Number)    Identification No.)
   


 7733 Forsyth Boulevard, St. Louis, MO                    63105-1820
(Address of principal executive offices)                  (ZIP Code)


Registrant's telephone number,                         (314) 854-5200
    including area code

<PAGE>

Item 5.  Other Events
A press release was issued October 15, 1997.  The relevant portion of
the text of that release was as follows:

MALLINCKRODT BOARD DECLARES QUARTERLY DIVIDEND;
THREE DIRECTORS ELECTED AT COMPANY'S ANNUAL MEETING

     COSTA MESA, California, October 15, 1997 -- The board of
directors of Mallinckrodt Inc. (NYSE:MKG), meeting here, has declared
a quarterly dividend of 16.5 cents per share on the company's common
stock, payable December 31, 1997, to shareholders of record at the
close of business on December 8, 1997.
     A regular $1 per share quarterly dividend on Mallinckrodt's 4
percent cumulative preferred stock, also payable on December 31,
1997, to shareholders of record at the close of business on December
8, 1997, also was declared.
     Shareholders attending the company's annual meeting today were
told that the integration of the company's largest-ever acquisition,
Nellcor Puritan Bennett, is on course.  As part of the meeting,
Mallinckrodt announced that it plans to divest a Nellcor Puritan
Bennett subsidiary, Puritan-Bennett Aerosystems Company.  This
subsidiary makes sophisticated emergency oxygen systems for
passengers and crew of commercial and private aircraft, and aircraft
video systems used for safety and entertainment.
     Mallinckrodt previously had announced that it expects some
earnings weakness in the first quarter but believes it can meet
consensus analyst earnings estimates for fiscal 1998.  The company's
first-quarter earnings will be announced October 23.
     C. Ray Holman, Claudine B. Malone and Anthony Viscusi were
elected to three-year terms on the Mallinckrodt board of directors. 
All three already serve on the board.
     In other business, stockholders approved a proposal to
discontinue the Directors' Retirement Plan and replace it with a
Directors' Stock Award Plan.  Performance goals for the company's
Long-Term Incentive Compensation Plan were approved, as was a
stockholder proposal to recommend that the board of directors redeem
or submit to a binding shareholder vote the company's Shareholder
Rights Plan.
     Mallinckrodt Inc. serves healthcare and specialty chemicals
markets worldwide.  The company has four major businesses -
pharmaceuticals, diagnostic imaging, respiratory care and specialty
chemicals.  The St. Louis, Missouri-based company, with fiscal 1997
net adjusted sales of $1.9 billion, operates in more than 100
countries.  The Mallinckrodt web site address is
(www.mallinckrodt.com).
                             # # #

Mallinckrodt Inc.



ROGER A. KELLER
Vice President, Secretary
and General Counsel

DATE:  October 16, 1997



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission